Search - tctmd.com

Displaying 1 - 20 of 57

Sort: Relevancy | Date

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

Todd Neale

December 26, 2025

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

L.A. McKeown

May 10, 2024

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Daily News

Class I Recall for Cordis’ Super Torque Catheters with Radiopaque Markers

Michael O'Riordan

September 23, 2021

The finding, from a study with a mean follow-up of 2-and-a-half years, bolsters support for trials and device use to continue.

News Daily News

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

L.A. McKeown

December 18, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Todd Neale

August 07, 2019

News Industry News

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

August 07, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

Advertisement

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Class I Recall for Cordis’ Super Torque Catheters with Radiopaque Markers

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

FDA’s First Take on New Paclitaxel Concerns in CLI

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content